



YEAR-END REPORT

September 2025 – August 2026

Diamyd Medical AB (publ), Fiscal year 2025/2026

Financial summary (September 2025 – August 2026)

- Net sales: MSEK 0.5 (0.1), fourth quarter: MSEK 0.1 (0.0)
- Net result: MSEK -255.6 (-169.8), fourth quarter: MSEK -16.8 (-44.9)
- Result per share before and after dilution: SEK -1.8 (-1.5), fourth quarter: SEK -0.1 (-0.3)
- Cash flow from operating activities: MSEK -195.3 (-169.7), fourth quarter: MSEK -40.4 (-35.9)
- Cash and short-term investments on August 31, 2026: MSEK 305.4 (277.2)
- The Board proposes that no dividend be paid for the financial year 2025/26

Events during the fourth quarter (June – August 2026)

- Diamyd Medical provided an update on ongoing activities
- Diamyd Medical received 'Notice of Allowance' for Key Precision Medicine Patent in the US
- Diamyd Medical provided an update regarding strategic overview
- Mathias Skalmstad started the position as CFO for Diamyd Medical
- Diamyd Medical provided an update on learnings from DIAGNODE-3 interim analysis

Events after the fourth quarter

- ASSET partnership, coordinated by Diamyd Medical, concluded five-year innovation program with final conference on precision medicine and the future of screening
- Diamyd Medical announced that results from the DiAPREV-IT study, published in journal Diabetologia, show that Diamyd's recombinant retogatein delays the onset of insulin-dependent type 1 diabetes by more than five years

Comments by CEO

Dear Shareholders,

The past year has been one of challenges, discipline, and renewed focus for Diamyd Medical. Following the decision to close the DIAGNODE-3 study, we acted decisively to reduce costs, preserve our financial strength, and reassess where we believe the company can create the greatest shareholder value. Expenses associated with closing the study have now been taken, and based on our approved budget, our current cash position is expected to fund operations for more than two years.

I am pleased to share encouraging news regarding our retogatein (GAD-alum) drug candidate. A peer-reviewed publication in *Diabetologia* reported that retogatein may delay progression from early, non-insulin-requiring Type 1 Diabetes (Stage 1 and 2 T1D) to insulin-requiring Stage 3 disease by more than five years in a genetically defined subgroup. This randomized study evaluated individuals with GAD autoantibodies and at least one additional islet autoantibody who had not yet progressed to insulin-requiring disease. With this finding, Diamyd Medical is actively engaging with clinical investigators on the potential design of clinical trials seeking to identify individuals who match retogatein's genetically defined responder profile, persons who could represent a relevant population for future treatment. We are also continuing discussions with pharmaceutical companies that see potential strategic value in retogatein as a complement to their metabolic and autoimmune disease portfolios.

Given our strong cash position, we also evaluated a range of investment opportunities during the past quarter, both within and outside Type 1 Diabetes therapeutics, including other autoimmune disease areas. This process reaffirmed our belief that the company's greatest strengths reside in its current drug candidates, including retogatein.

Retogatein has demonstrated a favorable safety profile across more than 15 clinical studies involving over 1,000 patients. Together with the encouraging results described above, these data strengthen our interest in developing retogatein as a potential therapy to delay or prevent progression to insulin-requiring Type 1 Diabetes. We believe this represents a logical path forward for Diamyd Medical to pursue. Another potential target population is patients with Latent Autoimmune Diabetes in Adults (LADA), which may account for approximately 10% of patients initially diagnosed with Type 2 Diabetes and may instead have autoimmune diabetes. We also remain open to participating with retogatein in investigator-initiated studies, and several discussions are ongoing. Taken together, the characteristics of retogatein provide a compelling basis for continued development: a long-term efficacy signal extending beyond five years; antigen-specific immune tolerance rather than broad immunosuppression; a favorable safety profile; an identified genetically defined responder group; and straightforward administration for patients.

Our GMP-approved biomanufacturing facility in Umeå is operational, with the next batch of retogatein drug substance scheduled for production before the end of the year. Diamyd Medical is open to working with partners on Contract Development and Manufacturing Organization projects, including those that contribute to preparedness and manufacturing capabilities in the event of future pandemics and other biological threats.

The company intends to remain open to selected, limited investments that have the potential to generate additional value over a two- to three-year horizon. Diamyd Medical currently holds investments in NextCell Pharma and Waterise.

Another recently formed initiative is the company's development of DiaTrapper, an AI-based application trained using datasets from various Type 1 Diabetes-related research efforts. The application is one outcome of the Vinnova-financed ASSET project. It is intended to assess an individual's risk of progressing to Stage 3 Type 1 Diabetes over time.

Our priorities are clear: advance retogatein toward the market for the early stages of Type 1 Diabetes; expand our Biomanufacturing activities in Umeå to include additional projects; continue and broaden partner discussions; and remain open to limited investments in promising assets.

I look forward to the coming years with great enthusiasm. The long-term data strengthen our conviction that retogatein deserves continued development. At the same time, our financial position and focused strategy provide Diamyd Medical with a disciplined pathway to pursue that opportunity. I strongly believe in retogatein and its potential to make a meaningful difference for people at risk of progressing to insulin-requiring Type 1 Diabetes.

This optimism would not be possible without the support of two special groups deserving our appreciation. First, I thank our more than 18,000 shareholders and supporters, including Breakthrough T1D, for their continued support. I also want to express my sincere gratitude to the over 1,000 patients who have participated in clinical studies with retogatein as part of our efforts to combat autoimmune Type 1 Diabetes.

Stockholm, October 7, 2026

Anders Essen-Möller, CEO



Drugs in clinical development

Retogatein is an antigen-specific, immunomodulatory precision medicine in clinical development for the treatment and prevention of type 1 diabetes. Retogatein has shown safety in clinical studies with more than 1,000 patients and has been granted Orphan Drug Designation in the U.S. as well as Fast Track Designation by the U.S. FDA for the treatment of Stage 3 (symptomatic) type 1 diabetes. Retogatein has also been granted Fast Track Designation for the treatment of Stage 1 and 2 (pre-symptomatic) type 1 diabetes. The Phase 3 trial DIAGNODE-3 and the Phase 2 trial DiaPrecise are both early terminated. The decision was taken in spring 2026 after the predefined interim efficacy analysis in DIAGNODE-3 did not demonstrate statistical significance on the primary efficacy endpoint. In addition, the pre-specified criteria for continuation of the trial were not met. Based on these results, the Company has decided to close DIAGNODE-3 for futility. Retogatein has recently been reported to delay disease progression into Stage 3 Diabetes and may be reassessed for prevention of Stage 3.

Remygen[®] is an oral investigational medicine based on GABA with potential regenerative and immunomodulatory effects for the treatment of type 1 and type 2 diabetes. The safety of Remygen[®] has been demonstrated in a Phase 1/2 clinical trial with Remygen[®] in individuals who have had type 1 diabetes for several years.

Biomanufacturing in Umeå

A biomanufacturing facility for biological products has been established in Umeå, Sweden. The facility is primarily developed for the manufacture of recombinant GAD65, the active pharmaceutical ingredient (API) in the Precision Medicine immunotherapy retogatein candidate. GMP certification and manufacturing authorization to produce clinical material were approved in May 2026.

The approximately 24,000 square foot multipurpose site includes clean rooms, laboratory facilities, warehousing, and office space, providing strong capabilities for scalable and controlled biomanufacturing. Diamyd Medical has implemented Cytiva's configurable single-use bioprocess platform FlexFactory, based on a baculovirus-insect cell expression system.

Going forward, the facility may serve as a strategic manufacturing resource for biological substances in both internal and external pharmaceutical development projects. Additional opportunities will be evaluated to maximize the value of the facility, manufacturing platform, analytical laboratory, and in-house expertise.



"I am very proud of the team's efforts in establishing the manufacturing facility and successfully obtaining GMP certification for the manufacture of materials for clinical use"

Sofia Mayans, PhD, Head of Manufacturing Site



The employees at the Umeå facility are experts in recombinant manufacture of biologics, e.g., cell culture and protein purification, paving the way for new clinical trial materials.

Key figures for the Group

	3 months Jun-Aug 2025/26	3 months Jun-Aug 2024/25	12 months Sep-Aug 2025/26	12 months Sep-Aug 2024/25
Research and development costs, MSEK	0.4	-30.5	-180.1	-119.5
Liquid assets and short-term investments, MSEK	305.4	277.2	305.4	277.2
Solidity, %	67	79	67	79
Result per share, before and after dilution, SEK	-0.1	-0.3	-1.8	-1.5
Liquidity and short-term investment per share, SEK	2.0	2.0	2.0	2.0
Equity per share, SEK	1.6	2.0	1.6	2.0
Total Cash flow per share, SEK	0.0	-0.3	0.2	1.5
Share price per closing, SEK	1.02	11.30	1.02	11.30
Number of shares per closing	154 984 500	137 499 723	154 984 500	137 499 723
Average numbers of shares	154 984 500	137 499 723	145 174 897	112 524 911
Average number of employees	39	36	42	33

Consolidated statement of comprehensive income

KSEK	Note	3 months Jun-Aug 2025/26	3 months Jun-Aug 2024/25	12 months Sep-Aug 2025/26	12 months Sep-Aug 2024/25
OPERATING INCOME					
Net sales		65	18	478	130
Other operating income	2	1 355	839	4 205	4 885
TOTAL OPERATING INCOME		1 420	857	4 682	5 015
OPERATING EXPENSES					
External research and development costs*		439	-30 477	-180 128	-119 504
External patent- and license costs		-73	-718	-2 761	-3 835
Personnel costs	3	-12 230	-9 860	-52 380	-39 224
Other external costs	4	-4 050	-4 258	-18 451	-17 327
Other operating expenses		-295	-303	-1 516	-1 855
Depreciation and impairment of tangible and intangible assets		-1 729	-1 755	-7 023	-6 504
TOTAL OPERATING EXPENSES		-17 939	-47 372	-262 259	-188 251
OPERATING RESULT		-16 519	-46 514	-257 577	-183 236
FINANCIAL INCOME AND EXPENSES					
Profit/loss of sold shares or other securities		-46	-	438	7 465
Impairment of participation in other companies		-88	-	-88	-508
Impairment of participation in associated companies		-	-	-1 264	-
Interest income and similar profit items		1 739	1 650	6 421	10 204
Interest expense and similar loss items		-1 896	-	-3 523	-3 702
TOTAL FINANCIAL INCOME AND EXPENSES		-291	1 650	1 984	13 459
RESULT AFTER FINANCIAL INCOME AND EXPENSES		-16 810	-44 864	-255 593	-169 777
Income tax		-	-	-	-
NET RESULT FOR THE PERIOD		-16 810	-44 864	-255 593	-169 777

*The provision for close-down costs related to DIAGNODE-3 was adjusted during the quarter and amounted to approximately 32,509 KSEK as of the reporting date.

Consolidated balance sheet

KSEK	Note	31 Aug 2026	31 Aug 2025
ASSETS			
NON-CURRENT ASSETS			
<i>Intangible assets</i>			
Patents		-	-
<i>Tangible assets</i>			
Land and buildings		27 429	28 837
Constructions in progress		-	988
Machinery and equipment		19 219	22 877
<i>Financial assets</i>	5		
Deferred tax		132	193
Participation in associated companies		-	1 264
Participation in other companies		9 162	5 984
Other long-term receivables		-	91
TOTAL NON-CURRENT ASSETS		55 943	60 233
CURRENT ASSETS			
Trade receivables		57	-
Other receivables		2 650	4 093
Prepaid expenses and accrued income		1 177	11 126
Liquid assets		305 426	277 185
TOTAL CURRENT ASSETS		309 310	292 404
TOTAL ASSETS		365 253	352 638

KSEK	Note	31 Aug 2026	31 Aug 2025
EQUITY AND LIABILITIES			
EQUITY			
Share capital		15 719	13 945
Other contributed capital		1 099 579	884 668
Other equity incl. result for the year		-871 710	-618 615
TOTAL EQUITY		243 588	279 999
PROVISIONS			
Pensions and other obligations		-	113
Other provisions		32 509	-
TOTAL PROVISIONS		32 509	113
LONG TERM-LIABILITIES			
Other long-term liabilities	6	55 090	45 043
TOTAL LONG-TERM LIABILITIES		55 090	45 043
CURRENT LIABILITIES			
Trade payables		20 914	11 962
Other payables		6 289	7 916
Prepaid income and accrued expenses		6 863	7 605
TOTAL CURRENT LIABILITIES		34 066	27 483
TOTAL EQUITY AND LIABILITIES		365 253	352 638

Consolidated statement of cash flow

KSEK	Note	3 months Jun-Aug 2025/26	3 months Jun-Aug 2024/25	12 months Sep-Aug 2025/26	12 months Sep-Aug 2024/25
OPERATING ACTIVITIES					
Operating profit/loss		-16 519	-46 514	-257 577	-183 236
Interest received		820	7 067	5 068	8 517
Interest paid		-1 896	-2 631	-2 837	-2 631
<i>Non-cash flow items</i>					
Depreciation		1 729	1 645	7 023	6 504
Other non-cash flow items		-37 783	941	35 033	2 043
CASH FLOW FROM OPERATING ACTIVITIES BEFORE CHANGES IN WORKING CAPITAL		-53 649	-39 492	-213 290	-168 803
Increase (-) decrease (+) accounts receivable		-20	41	-57	23
Increase (-) decrease (+) other receivables		1 265	2 687	1 444	-1 388
Increase (-) decrease (+) prepaid expenses/accrued income		650	2 969	9 949	12 924
Increase (-) decrease (+) trade payables		13 802	-1 027	8 953	-4 644
Increase (-) decrease (+) other liabilities		-1 431	-467	-1 566	-901
Increase (+) decrease (-) accrued expenses/deferred income		-1 022	-656	-743	-6 894
NET CASH FLOW FROM OPERATING ACTIVITIES		-40 405	-35 944	-195 311	-169 683
INVESTING ACTIVITIES					
Investment in tangible assets		-	-2 184	-992	-10 048
Investment in financial assets		-4 446	-	-4 446	-608
Disposal of financial assets		1 058	-	1 132	1 008
Profit on disposal of financial assets		-	-	485	7 211
Matured short-term investments		-159 008	-	-99 371	19 608
Investment in short term investments		198 741	-	99 371	-
NET CASH FLOW FROM INVESTING ACTIVITIES		36 345	-2 184	-3 820	17 171
FINANCING ACTIVITIES					
New issue		-	-	233 247	315 392
Issue expense		-	-567	-16 589	-13 441
Long-term liabilities	6	1 896	-507	10 047	14 371
NET CASH FLOW FROM FINANCING ACTIVITIES		1 896	-1 074	226 705	316 322
TOTAL CASH FLOW FOR THE PERIOD		-2 165	-39 202	27 574	163 810
Cash and cash equivalents at beginning of period		306 672	319 262	277 185	112 758
Net foreign exchange difference		919	-2 874	667	617
CASH AND CASH EQUIVALENTS AT END OF PERIOD		305 426	277 185	305 426	277 185

Consolidated statement of changes in equity

KSEK	Share Capital	Other contributed capital	Other equity incl. result for the year	Total Shareholders' equity
OPENING BALANCE SEPTEMBER 1, 2024	10 114	586 549	-450 742	145 920
Net result	-	-	-169 777	-169 777
New issue	3 831	311 561	-	315 392
Issue expenses	-	-13 441	-	-13 441
Incentive program LTI 2022	3	-	911	911
Incentive program LTI 2024	3	-	875	875
Incentive program Board LTI 2024	3	-	119	119
CLOSING BALANCE AUGUST 31, 2025	13 945	884 668	-618 614	279 999
OPENING BALANCE SEPTEMBER 1, 2025	13 945	884 668	-618 614	279 999
Net result	-	-	-255 593	-255 593
New issue	1 747	231 500	-	233 247
Issue expenses	-	-16 589	-	-16 589
Incentive program LTI 2022	3	26	573	599
Incentive program LTI 2024	3	-	1 712	1 712
Incentive program Board LTI 2024	3	-	212	212
CLOSING BALANCE AUGUST 31, 2026	15 719	1 099 579	-871 710	243 588

Income statement for the parent company

KSEK	Note	3 months Jun-Aug 2025/26	3 months Jun-Aug 2024/25	12 months Sep-Aug 2025/26	12 months Sep-Aug 2024/25
OPERATING INCOME					
Net sales		112	105	748	525
Other operating income	2	1 355	839	4 205	4 885
TOTAL OPERATING INCOME		1 467	944	4 953	5 410
OPERATING EXPENSES					
External research and development costs*		439	-30 477	-180 128	-119 504
External patent- and license costs		-73	-718	-2 761	-3 835
Personnel costs	3	-12 230	-9 860	-52 380	-39 224
Other external costs	4	-4 685	-4 743	-20 765	-18 080
Other operating expenses		-295	-303	-1 516	-1 855
Depreciation and impairment of					
Tangible and intangible assets		-1 270	-1 241	-5 066	-4 388
TOTAL OPERATING EXPENSES		-18 115	-47 343	-262 616	-186 887
OPERATING RESULT		-16 648	-46 399	-257 664	-181 477
FINANCIAL INCOME AND EXPENSES					
Profit/loss of sold shares or other securities		-46	-	438	7 465
Impairment of shares in associated companies		-	-	-1 264	-
Impairment of participation in other companies		-88	-	-88	-508
Interest income and similar profit items		1 854	1 841	6 952	10 998
Interest expense and similar loss items		-1 896	-	-3 523	-3 702
TOTAL FINANCIAL INCOME AND EXPENSES		-176	1 841	2 516	14 253
RESULT BEFORE TAXES		-16 824	-44 557	-255 148	-167 225
Income tax		-	-	-	-
NET RESULT FOR THE PERIOD		-16 824	-44 557	-255 148	-167 225

* The provision for close-down costs related to DIAGNODE-3 was adjusted during the quarter and amounted to approximately 32,509 KSEK as of the reporting date.

Balance sheet for the parent company

KSEK	Not	31 Aug 2026	31 Aug 2025
ASSETS			
NON-CURRENT ASSETS			
<i>Intangible assets</i>			
Patents		-	-
<i>Tangible assets</i>			
Machinery and equipment		18 959	23 263
<i>Financial assets</i>	5		
Shares in subsidiaries		16 291	16 291
Long-term receivables from subsidiaries		15 000	15 000
Participation in associated companies		-	1 264
Participation in other companies		9 163	5 984
Other long-term receivables		-	91
TOTAL NON-CURRENT ASSETS		59 413	61 892
CURRENT ASSETS			
Trade receivables		41	-
Receivables subsidiaries		238	809
Other receivables		2 517	3 972
Prepaid expenses and accrued income		1 155	11 095
Liquid assets and short-term investments		304 108	276 443
TOTAL CURRENT ASSETS		308 059	292 319
TOTAL ASSETS		367 472	354 211

KSEK	Not	31 Aug 2026	31 Aug 2025
EQUITY AND LIABILITIES			
EQUITY			
<i>Restricted equity</i>			
Share capital		15 719	13 945
Statutory reserve		200	200
<i>Non restricted equity</i>			
Share premium reserve non-restricted		1 099 379	884 468
Profits or loss brought forward		-613 886	-449 158
Net result for the period		-255 148	-167 225
TOTAL EQUITY		246 264	282 231
PROVISIONS			
Pensions and other obligations		-	113
Other provisions		32 509	-
TOTAL PROVISIONS		32 509	113
LONG-TERM LIABILITIES			
Other long-term liabilities	6	55 090	45 043
TOTAL LONG-TERM LIABILITIES		55 090	45 043
CURRENT LIABILITIES			
Trade payables		20 870	11 597
Other payables		5 946	7 622
Payables subsidiaries		-	-
Prepaid income and accrued expenses		6 793	7 605
TOTAL CURRENT LIABILITIES		33 609	26 824
TOTAL EQUITY AND LIABILITIES		367 472	354 211

Notes

Note 1 – General information and accounting principles

This interim report includes the parent company Diamyd Medical AB (publ), Corp. Reg. No. 556242-3797 and the subsidiary Diamyd Biomanufacturing AB, Corp. Reg. No. 559041-0931. Unless otherwise stated, all amounts are in thousands of Swedish kronor (KSEK). Figures, if not otherwise stated, refer to the Group.

Interim and annual reports are prepared with the application of the Annual Accounts Act and the Swedish Accounting Standards Board BFNAR 2012: 1 Annual Report and Consolidated accounts (K3).

Note 2 – Other operating income

Other operating income consists mainly of grants related to VINNOVA (Swedish innovation agency) financed projects.

Note 3 – Long-term Incentive programs

LTI 2022

Incentive program LTI2022 was finalized during the financial year, and shares were allocated to participants at quota value.

LTI 2024

The Company had as of August 31, 2026, allocated 45 participants rights to performance shares in accordance with LTI 2024. A total of 450 000 rights to performance shares have been allocated. LTI 2024 rights are measured on the allotment date at fair value of allocated equity instruments. As of August 31, 2026, social costs for LTI 2024 amounted to MSEK 0.0 and personnel costs MSEK 1.71 for the period. The personnel cost was based on the allocation value, simulated with the Monte Carlo method.

Board LTI 2024

The Company had as of August 31, 2026, allocated 6 participants rights to performance shares in accordance with Board LTI 2024. A total of 60 000 rights to performance shares have been allocated. Board LTI 2024 rights are measured on the allotment date at fair value of allocated equity instruments. As of August 31, 2026, social costs for Board LTI 2024 amounted to MSEK 0.0 and personnel costs MSEK 0.21 for the period. The personnel cost was based on the allocation value, simulated with the Monte Carlo method.

Note 4 – Related-party transactions

During the period companies represented by immediate family members of the main owner and Executive Chairman Anders Essen-Möller were contracted as consultants. Total compensation for consultancy services and salaries to immediate family members amounted to KSEK 2 267 (2 229). Anders Essen-Möller has through a company owned by Essen-Möller been compensated by KSEK 794 (3 257). Pricing has been set by the arm's length principle.

Group and parent company

KSEK	Sep-Aug 2025/26	Sep-Aug 2024/25
Consultant fees and salary to related parties	2 267	2 229
Consultant fees to Board members	794	3 257

Note 5 – Financial assets

Parent company

Diamyd Medical AB owns shares in NextCell Pharma AB (corporate registration no 556965-8361) who develops stem cell therapies and operates a stem cell bank for private family saving of stem cells. As of August 31, 2026, the carrying amount was MSEK 4.7. Diamyd Medical's share of the equity as well as share of the votes was approximately 4 %, as of the same date.

Diamyd Medical AB owns preference shares in Waterise B.V. (trade register number 88419398) who specialize in providing sustainable freshwater solutions through innovative desalination technology. As of August 31, 2026, the carrying amount was MSEK 4.4.

Note 6 – Long-term liabilities

Group and parent company

KSEK	Sep-Aug 2025/26	Sep-Aug 2024/2025
Opening balance (Breakthrough T1D)	45 043	30 672
Other long-term liabilities (Breakthrough T1D)	10 047	14 371
Closing balance	55 090	45 043

Diamyd Medical receives financing within its partnership with Breakthrough T1D (formerly JDRF), when certain milestones have been reached. If Diamyd Medical obtains commercial approval for retogatein and sales of the drug are commercially successful, Breakthrough T1D will receive limited royalties. As a result of Diamyd Medical's commitment pertaining to future royalties, payments from Breakthrough T1D are recognized as long-term liabilities.

Risks

Diamyd Medical's operations are associated with risks related to inter alia drug development, commercialization, financing, intellectual property, collaborations with partners, authority decisions, agreements, and key personnel. For a description of the Company's risks, please see the Annual Report for the fiscal year 2024/2025. No significant changes in the Company's risk assessment have occurred since the Annual Report was issued.

Statement

The Board of Directors and the CEO certify that this interim report gives a fair overview of the business, position and profit or loss of the Company and describes the principal risks and uncertainties that the Company faces. This report has not been reviewed by the Company's auditors.

Stockholm, October 7, 2026

Erik Nerpin
Chairman of the Board

Anders Essen-Möller
CEO, Board member

Maria-Teresa Essen-Möller
Board member

Torbjörn Bäckström
Board member

Mark A. Atkinson
Board member

Karin Hehenberger
Board member

Karin Rosén
Board member

Financial Calendar

Annual Report
Annual General Meeting
Quarterly Report 1
Quarterly Report 2
Quarterly Report 3
Year-end Report

November 12, 2026
December 3, 2026
January 26, 2027
April 27, 2027
June 29, 2027
October 26, 2027

About Diamyd Medical

Diamyd Medical is a Swedish biotechnology company focused on precision medicine approaches for type 1 diabetes and biological manufacturing. The company's lead investigational drug candidate is retogatein (GAD-alum), based on recombinant GAD65. The Company has established a GMP-approved facility for manufacturing of biological products in Umeå, Sweden.

Diamyd Medical's B share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company's Certified Adviser. Further information is available on <https://www.diamyd.com>

For more information, please contact:

Anders Essen-Möller, CEO, anders.essen-moller@diamyd.com

Diamyd Medical AB (publ), Box 7349, SE-103 90 Stockholm, Sweden

Phone: +46 8 661 00 26 E-mail: mailto:info@diamyd.com Reg. no: 556242-3797

The information was submitted for publication, through the agency of the contact persons set out above, at 08.15 CET on October 7, 2026.